^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Lymphocytic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    BeiGene Press Release
    Title:

    BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

    Published date:
    12/07/2020
    Excerpt:
    BeiGene....announced that the China National Medical Products Administration (NMPA) has approved BLINCYTO (blinatumomab) for injection for the treatment of adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Acute Lymphoblastic leukemia: Option added: Blinatumomab ± TKI
    Secondary therapy:
    Tyrosine Kinase Inhibitors
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Acute Lymphoblastic leukemia: Option added: Blinatumomab ± TKI
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Amgen Press Release
    Title:

    BLINCYTO (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

    Published date:
    03/02/2021
    Excerpt:
    Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)...BLINCYTO demonstrated significantly prolonged event-free survival...